An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Latest Information Update: 07 Oct 2025
At a glance
- Drugs Mesenchymal stem cell therapies (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Therapeutic Use
- Sponsors Cell Biopeutics Resources
Most Recent Events
- 09 Sep 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
- 09 Sep 2025 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2027.
- 06 Feb 2024 Status changed from not yet recruiting to recruiting.